ibrutinib,venetoclax,obinutuzumab
abbvie,janssen,roche
['cll', 'obinu', 'venetoclax', ' ibru', 'glow', 'lymsm']
congress | #ash22 , presents follow-up data from the glow study on residual disease kinetics among pts with high-risk factors treated ibr+ven vs clb+o. the ibr+ven combination achieved superior umrd responses.
#lymsm #medicalcongress #hematology 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm